Eczema is a chronic relapsing dermatitis and, as such, it is imperative to maintain the hydration and barrier function of the skin in these patients with daily moisturizer use. This article discusses TEWL, ceramide and urea based moisturizers, and other ways to maintain barrier function.
The cosmeceutical industry has undergone phenomenal growth over the past decade, and much of this expansion can be attributed to an aging population wanting to sustain a youthful appearance. Keeping abreast of the latest findings and newest product offerings has become important for providing accurate advice to patients. Products supported by scientific research can be effective as an adjunct to therapy.
Topical treatment is the mainstay for mild acne, and adjunctive to oral or hormonal therapy for moderate acne. This article explores recent formulary advances and offers clinical strategies that can encourage adherence and improve treatment outcomes.
Atopic eczema is a chronic condition and a long view is necessary for disease control and management. This article discusses the important role of the skin barrier and how it may be a target for therapeutics in treating atopic eczema.
The prevalence of eczema is increasing over the past 30 years, and is estimated to affect 20% of children in North America and Northern Europe. This article discusses eczema, incidence, clinical presentations, and management, as well as specific primary and second line therapies.
A summary of a panel discussion between 4 established dermatologists at Dermatology Update in Whistler, British Columbia. An effort to establish a professional review process for OTC products, as the demand for clarity is increasingly demanded from consumers, and dermatologists are asked to opine on these non-prescription products more commonly.
This article delves into appropriate use of topical therapies for acne treatment. Appropriate agent selection, tolerance, adherence, follow-up, and considerations like complexity of treatment are discussed.
Patients suffering from scalp psoriasis frequently seek medical care because of the persistent discomfort due to itching and social embarrassment. This article explores some of the challenges that patients fact, current options and new advances in the topical management and strategies that may improve treatment outcomes.
Acne is among the most common dermatological disorders seen by dermatologists, affecting approximately 85% of people between the ages of 12 and 24 years. The use of adjunctive cleansers and moisturizers can help mitigate treatment side effects and subsequently enhance therapeutic efficacy.
Head lice infestation is a common problem for children in Canada. Diagnosis, and treatment are discussed as well as the problem of heritable resistance, and alternate treatments.
Hand dermatitis (HD) is a common skin disorder affecting individuals of all ages. This article discusses diagnostics, individualizing treatments, lifestyle modifications, and outcomes.
Personal care in Canada is a $5.0 billion industry that offers thousands of competing products, many of which make skin care-related claims. A new paradigm for reviewing non-prescription products.
This article focuses on topical D3 vitamin analogues for the treatment of psoriasis. Therapeutic efficacy, toxicity, patient adherence, combination therapy, and the family physician's role in psoriasis treatment are covered.
The role and importance of moisturizer in managing and controlling the symptoms of atopic dermatitis. As atopic dermatitis is a chronic condition, successful management requires a multipronged approach that includes lifestyle modification, adaptations to skin care practices, and medical intervention.
Actinic keratoses (AKs), or solar keratoses, are pre-malignant cutaneous lesions that predominantly manifest in sun-exposed areas. This article covers treatment regimens, sun protection, and the role that physicians play in improving patient awareness.
This article describes how pharmacists can play an important role in providing for patients with their skin concerns and counselling patients on effective management and behavioral strategies as well as prescribing. Reactive and proactive communication approaches are described.
Oral contraceptives (OCs) have been used for many years by dermatologists as a treatment option for women with acne. The proven therapeutic benefits of OCs extend a valuable alternative to physicians for the treatment of acne.
This article discusses the rationale behind various topical treatments for acne to increase adherence and optimize outcomes. Efficacy, safety, antibiotic resistance, onset of action, and combination therapies are covered.
A review of corticosteroids, including use, adverse effects, vehicle, generic vs brand name drugs. Physicians and pharmacists alike should be aware of the importance and the difference of various vehicles when prescribing topical corticosteroids.
Increasingly, patients are seeking medical consultation for the management of photodamage, actinic keratoses (AKs), and nonmelanoma skin cancer (NMSC), which is now a global epidemic. A comparative analysis of various treatment modalities are shown.
Hair loss is a common dermatological problem that affects a large segment of the population both physically and psychologically. Currently, only one topical agent is approved for treatment of hair loss in men, although other treatments are being clinically investigated.
Itch is a very common feature in a variety of skin conditions. Idiopathic or non-specific itch is also common, and presents a challenge for dermatologists to manage. Diagnosis, treatment, and management strategies for various itch are discussed in this article.
External genital warts (EGW) are a common infection caused primarily by human papillomavirus (HPV) types 6 and 11. This article discusses the pathogenesis of EGW, impact on patients, therapeutics, vaccination, and other topics.
Atopic dermatitis (AD) is a chronic, waxing and waning, often symmetric inflammatory eruption that is characterized by pruritus and xerosis. This article discusses the role of creams in normalizing the barrier function early, and preventing inflammation processes from starting.
Skin Treatments Introduced in 2012 including CIP-Isotretinoin capsule Epuris™(in Canada) Absorica™(in US), Lidocaine 7% + tetracaine 7% cream Pliaglis®, Collagenase clostridium histolyticum Xiaflex®, C1 esterase inhibitor (human) Cinryze®, Ipilimumab Yervoy™, and Vemurafenib tablets Zelboraf™.